Glyxambi for Type 2 Diabetes

By GabbyPA Latest Reply 2015-02-24 13:53:39 -0600
Started 2015-02-24 10:07:57 -0600

"Glyxambi is the first-ever SGLT-2/DPP-4 inhibitor combination drug to be approved in the US. It will be available in two doses (10 mg empagliflozin/5 mg linagliptin and 25 mg empagliflozin/5 mg linagliptin) to be taken once-daily in the morning. It is recommended for people with type 2 diabetes who are not reaching their A1c goals with current drugs. There is no information yet on pricing or insurance coverage for Glyxambi (at least not any we could find!). In short, the advantages of Glyxambi are convenience (single pill), potentially lower cost (one co-pay), and a relatively mild side-effect profile for most patients. For more background on SGLT-2/DPP-4 inhibitor fixed dose combinations, please see our recent learning curve on the topic." - See more at:

2 replies

JoleneAL 2015-02-24 12:04:14 -0600 Report

One drug uses the kidneys, the other doesn't. So this combined drug may not work for those with kidney issues.

GabbyPA 2015-02-24 13:53:39 -0600 Report

I am sure we all would need to talk to our doctors if we chose to try something along these lines. It's just always interesting to see what is out there and find out if anyone has used it and how it works for them.